已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Accreditation drives teaching: evidence-based medicine and medical education standards

医学 内科学 急性肾损伤 透析 传统PCI 心脏病学 心肌梗塞 肌酐 经皮冠状动脉介入治疗 肾功能 肾脏替代疗法
作者
Ahmed Rashid,Samuel Finnikin,Sean Tackett
出处
期刊:BMJ evidence-based medicine [BMJ]
卷期号:26 (5): 216-218 被引量:4
标识
DOI:10.1136/bmjebm-2020-111491
摘要

Objective

To investigate the long-term prognostic implications of contrast-induced acute kidney injury (CI-AKI) with transient or persistent renal dysfunction in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI).

Design

A retrospective observational registry study.

Setting

Clinical follow-up after PCI.

Patients and Methods

A total of 1041 PCI-treated AMI patients from the Infarction Prognosis Study registry. CI-AKI was defined as an increase in serum creatinine (>25% or >0.5 mg/dl (>44.2 μmol/l)) within 2 days after PCI.

Main Outcome Measures

Two-year cumulative event rate of all-cause death or renal failure requiring dialysis.

Results

CI-AKI was observed in 148 patients (14.2%). Patients with CI-AKI had a higher rate of death or dialysis (25.4% vs 6.3%, p<0.001) at 2 years compared with patients without CI-AKI. CI-AKI was an important independent predictor of death or dialysis (HR 2.76, 95% CI 1.61 to 4.73, p<0.001) Persistent renal dysfunction after CI-AKI was documented in 68 patients (45.9%). Patients with transient renal dysfunction showed a lower 2-year event rate of death or dialysis compared with those with persistent renal dysfunction (17.9% vs 34.1%, p=0.013); however, they showed a higher event rate compared with those without CI-AKI (17.9% vs 6.3%, p<0.001).

Conclusion

Transient and persistent renal dysfunction after CI-AKI was associated with increased short and long-term mortality and morbidity in AMI patients treated by PCI. Better preventive strategies are needed to improve clinical outcomes in AMI patients at high risk of developing CI-AKI.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gt发布了新的文献求助10
1秒前
终止密码子完成签到 ,获得积分10
1秒前
孤独书白发布了新的文献求助10
2秒前
传奇3应助刘思睿采纳,获得10
2秒前
桐桐应助凄凉山谷的风采纳,获得10
5秒前
orixero应助老大爱贴纸采纳,获得30
6秒前
9秒前
9秒前
sleepydoudou完成签到,获得积分10
10秒前
12秒前
13秒前
脱羰甲酸发布了新的文献求助10
13秒前
鲤跃完成签到,获得积分10
14秒前
雪满头应助gt采纳,获得10
14秒前
雪满头应助gt采纳,获得10
14秒前
852应助xhj采纳,获得10
14秒前
小苏完成签到 ,获得积分10
16秒前
17秒前
鲤跃发布了新的文献求助10
17秒前
早茶可口完成签到,获得积分10
19秒前
20秒前
gt完成签到,获得积分10
22秒前
充电宝应助翁宇轩采纳,获得10
24秒前
25秒前
Hu完成签到,获得积分10
26秒前
28秒前
何曼慈应助难过谷雪采纳,获得10
29秒前
30秒前
35秒前
35秒前
39秒前
小王同志发布了新的文献求助10
40秒前
郭郭完成签到 ,获得积分10
41秒前
yangxiaoyang发布了新的文献求助10
41秒前
42秒前
孤独书白完成签到,获得积分10
43秒前
翁宇轩发布了新的文献求助10
44秒前
清脆咖啡完成签到,获得积分10
46秒前
Yantuobio完成签到,获得积分10
46秒前
起风了完成签到,获得积分10
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6965658
求助须知:如何正确求助?哪些是违规求助? 8647279
关于积分的说明 18338717
捐赠科研通 6417711
什么是DOI,文献DOI怎么找? 3087526
关于科研通互助平台的介绍 2137960
邀请新用户注册赠送积分活动 2064116